Hot Investor Mandate: Corporate VC Arm of Conglomerate Invests in Series A to B Rounds in Therapeutics, Diagnostics, and Digital Health, With Interest in Large Market Opportunities

11 Aug

A corporate venture arm under a large conglomerate invests in a wide range of industries including biotech, ICT, media, food, among others. With regards to life sciences and healthcare, The firm generally invests in Series A to B rounds but has participated in as early as pre-Series A. Typical initial size of investment is over $1M, and is subject to larger amounts depending on the stage of the company. The firm has invested mostly in USA and Korea, but is open to considering global opportunities.

The firm will consider opportunities across therapeutics, diagnostics, digital health. Within these sectors, the firm is most interested in drug discovery and development, diagnostics, digital health, and microbiome. In therapeutics, the firm is open to both pre-clinical and clinical assets & platforms and will consider all different types of modalities (small molecule, antibodies, cell/gene therapy). The firm will consider all indications but is interested in large markets including oncology/immuno-oncology and CNS.

The firm has no specific management team requirements. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: